Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions



Status:Recruiting
Conditions:Parkinsons Disease, Neurology, Gastrointestinal
Therapuetic Areas:Gastroenterology, Neurology
Healthy:No
Age Range:18 - 80
Updated:8/22/2015
Start Date:April 2014
End Date:November 2016
Contact:Public Disclosure Manager
Email:clinicaltrials@merz.de

Use our guide to learn which trials are right for you!

Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

The objective of this study is to investigate the efficacy and safety of two different dose
levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary
flow rate, and the severity and frequency of chronic troublesome sialorrhea that occurs as a
result of various neurological conditions in adult subjects.


Inclusion Criteria:

- Documented diagnosis of the basic neurological condition associated with sialorrhea
(as above, (i), (ii) or (iii); with onset at least 6 months before screening).

- Chronic troublesome sialorrhea related to parkinsonism or stroke or traumatic brain
injury (for at least 3 months) at screening, defined as the presence of all of the
following, at screening and at baseline and for at least the 3 months before
screening (where retrospective response to questionnaires is impossible, a statement
of equivalent severity will suffice):

1. A Drooling Severity and Frequency Scale [DSFS] sum score of at least 6 points
and

2. A score of at least 2 points for each item of the DSFS and

3. A score of at least 3 points on the modified Radboud Oral Motor Inventory for
Parkinson's Disease [mROMP], Section 'III Drooling', Item A).

- A score of at most 2 points on the mROMP Section 'II Swallowing Symptoms' Item A) and
a score of at most 3 points on Item C), at screening and at baseline.

Exclusion Criteria:

- Non-neurological secondary causes of sialorrhea.

- Unstable concomitant medication influencing sialorrhea (such as anticholinergics for
the treatment of parkinsonism; dosages of these medications must have been stable for
at least 4 weeks before study entry, i.e. screening, and must be planned to remain
stable during the course of the study.

- Recent (i.e., four weeks) drug treatment for sialorrhea.

- History of recurrent aspiration pneumonia.

- Extremely poor dental/oral condition as assessed by a qualified dentist.

- Recent (i.e., one year for sialorrhea, 14 weeks for other indications) treatment with
- or known hypersensitivity to - Botulinum toxin, or known hypersensitivity to any
ingredient of the study preparation.

- Recent (i.e., four weeks) changes in anti-parkinsonian medication.

- Previous or planned surgery or irradiation to control sialorrhea.
We found this trial at
1
site
Washington, District of Columbia 20007
?
mi
from
Washington,
Click here to add this to my saved trials